Novartis Said to Near at Least $70-Per-Share Deal for Avidity

Novartis AG is nearing a deal to buy biotechnology company Avidity Biosciences Inc., according to a person familiar with the matter.

By Michelle F Davis · Bloomberg

Novartis AG is nearing a deal to buy biotechnology company Avidity Biosciences Inc., according to a person familiar with the matter.